DURECT's lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy Designation Potential to be the first FDA-approved therapeutic...
Developing
Every year, 20 million people globally are diagnosed with cancer.1 Every patient is unique, with hundreds of distinct tumor sub-types,...
In developing countries, there is a serious shortage of electricity, primarily due to a lack of access to technology and...
